Does the media refer more to AUPH or IBRX?

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 6 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat ImmunityBio's score of 0.89 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunityBio 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMVT or AUPH?

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 5 mentions for Immunovant. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Immunovant's score of 1.18 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor APGE or AUPH?

In the previous week, Apogee Therapeutics had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 12 mentions for Apogee Therapeutics and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Apogee Therapeutics' score of 1.39 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor AUPH or TGTX?

In the previous week, TG Therapeutics had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat TG Therapeutics' score of 0.90 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive TG Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALKS or AUPH?

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 6 mentions for Alkermes. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Alkermes' score of 0.46 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Aurinia Pharmaceuticals (AUPH) Competitors

$16.29 +0.24 (+1.50%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$16.27 -0.02 (-0.12%)

As of 06:20 AM Eastern

Compare

AUPH vs. IBRX, IMVT, APGE, TGTX, and ALKS

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? Aurinia Pharmaceuticals's main competitors and comparable companies include ImmunityBio (IBRX), Immunovant (IMVT), Apogee Therapeutics (APGE), TG Therapeutics (TGTX), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to ImmunityBio's net margin of -598.55%. Aurinia Pharmaceuticals' return on equity of 26.11% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
ImmunityBio	-598.55%	N/A	-51.65%

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 6 mentions for ImmunityBio. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat ImmunityBio's score of 0.89 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, indicating a potential upside of 8.45%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 78.62%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts plainly believe ImmunityBio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aurinia Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11
ImmunityBio	$113.29M	74.37	-$351.40M	-$0.97	N/A

Summary

Aurinia Pharmaceuticals beats ImmunityBio on 12 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aurinia Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

Immunovant currently has a consensus target price of $44.00, indicating a potential upside of 11.42%. Aurinia Pharmaceuticals has a consensus target price of $17.67, indicating a potential upside of 8.45%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Immunovant has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Immunovant. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 5 mentions for Immunovant. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Immunovant's score of 1.18 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Immunovant's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Summary

Aurinia Pharmaceuticals beats Immunovant on 13 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Apogee Therapeutics presently has a consensus price target of $126.77, indicating a potential downside of 6.14%. Aurinia Pharmaceuticals has a consensus price target of $17.67, indicating a potential upside of 8.45%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Aurinia Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Apogee Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

In the previous week, Apogee Therapeutics had 4 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 12 mentions for Apogee Therapeutics and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Apogee Therapeutics' score of 1.39 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Apogee Therapeutics' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Summary

Aurinia Pharmaceuticals beats Apogee Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to TG Therapeutics' net margin of 55.22%. TG Therapeutics' return on equity of 73.49% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%
TG Therapeutics	55.22%	73.49%	34.14%

Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

TG Therapeutics has higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11
TG Therapeutics	$616.29M	14.13	$447.18M	$2.74	20.77

Aurinia Pharmaceuticals presently has a consensus target price of $17.67, suggesting a potential upside of 8.45%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 10.72%. Given TG Therapeutics' higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, TG Therapeutics had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 8 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat TG Therapeutics' score of 0.90 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
TG Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

TG Therapeutics beats Aurinia Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

95.2% of Alkermes shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aurinia Pharmaceuticals had 2 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Aurinia Pharmaceuticals and 6 mentions for Alkermes. Aurinia Pharmaceuticals' average media sentiment score of 1.60 beat Alkermes' score of 0.46 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aurinia Pharmaceuticals has lower revenue, but higher earnings than Alkermes. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.80	$241.66M	$0.38	125.58
Aurinia Pharmaceuticals	$283.05M	7.66	$287.20M	$2.29	7.11

Alkermes currently has a consensus target price of $54.56, suggesting a potential upside of 14.34%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 8.45%. Given Alkermes' stronger consensus rating and higher probable upside, equities research analysts plainly believe Alkermes is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Alkermes' net margin of 3.96%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Alkermes has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Alkermes on 10 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.14B	$3.99B	$7.21B	$12.67B
Dividend Yield	N/A	3.61%	2.53%	8.56%
P/E Ratio	7.11	12.25	272.66	25.23
Price / Sales	7.66	1,407.15	635.76	104.55
Price / Cash	15.84	105.29	76.98	52.08
Price / Book	3.53	16.14	12.83	6.10
Net Income	$287.20M	-$22.72M	$3.47B	$348.86M
7 Day Performance	-1.15%	-1.23%	-0.12%	-1.90%
1 Month Performance	11.81%	11.26%	6.74%	1.96%
1 Year Performance	35.75%	53.10%	25.09%	15.30%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	2.9105 of 5 stars	$16.29 +1.5%	$17.67 +8.5%	+39.5%	$2.14B	$283.05M	7.11	300
IBRX ImmunityBio	2.1616 of 5 stars	$7.95 -1.2%	$14.20 +78.6%	+234.0%	$8.53B	$113.29M	N/A	590
IMVT Immunovant	1.6646 of 5 stars	$40.82 -0.9%	$44.00 +7.8%	+162.0%	$8.51B	N/A	N/A	120	Positive News
APGE Apogee Therapeutics	1.5835 of 5 stars	$135.08 +0.1%	$126.77 -6.2%	+256.8%	$8.40B	N/A	N/A	91	Positive News
TGTX TG Therapeutics	2.9571 of 5 stars	$54.30 +0.7%	$63.00 +16.0%	+91.4%	$8.26B	$616.29M	19.82	290	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. IBRX, IMVT, APGE, TGTX, and ALKS

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Summary

How does Aurinia Pharmaceuticals compare to Alkermes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. IBRX, IMVT, APGE, TGTX, and ALKS

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Do institutionals and insiders believe in AUPH or IBRX?

Is AUPH or IBRX more profitable?

Does the media refer more to AUPH or IBRX?

Which has more volatility & risk, AUPH or IBRX?

Do analysts prefer AUPH or IBRX?

Which has higher earnings & valuation, AUPH or IBRX?

Summary

How does Aurinia Pharmaceuticals compare to Immunovant?

Do insiders & institutionals have more ownership in IMVT or AUPH?

Which has better valuation & earnings, IMVT or AUPH?

Do analysts recommend IMVT or AUPH?

Which has more risk and volatility, IMVT or AUPH?

Does the media favor IMVT or AUPH?

Is IMVT or AUPH more profitable?

Summary

How does Aurinia Pharmaceuticals compare to Apogee Therapeutics?

Do insiders and institutionals have more ownership in APGE or AUPH?

Do analysts recommend APGE or AUPH?

Which has more volatility and risk, APGE or AUPH?

Which has higher earnings and valuation, APGE or AUPH?

Does the media favor APGE or AUPH?

Is APGE or AUPH more profitable?

Summary

How does Aurinia Pharmaceuticals compare to TG Therapeutics?

Is AUPH or TGTX more profitable?

Which has more volatility and risk, AUPH or TGTX?

Which has better valuation and earnings, AUPH or TGTX?

Do analysts prefer AUPH or TGTX?

Does the media favor AUPH or TGTX?

Do insiders and institutionals hold more shares of AUPH or TGTX?

Summary

How does Aurinia Pharmaceuticals compare to Alkermes?

Do institutionals and insiders hold more shares of ALKS or AUPH?

Does the media prefer ALKS or AUPH?

Which has better valuation & earnings, ALKS or AUPH?

Do analysts prefer ALKS or AUPH?

Is ALKS or AUPH more profitable?

Which has more risk and volatility, ALKS or AUPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools